Lantz Keri
Form 3
January 07, 2019

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Expires:	January 31, 2005
Estimated average burden hours per response...	0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Â Lantz Keri
(Last) (First) (Middle)

C/O ACHILLION PHARMACEUTICALS, INC.,Â 300 GEORGE STREET
(Street)

NEW HAVEN,Â CTÂ 06511
(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2019

3. Issuer Name **and** Ticker or Trading Symbol
ACHILLION PHARMACEUTICALS INC [ACHN]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,848	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (*e.g.*, puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Employee Stock Option	Â (1)	12/18/2019	Common Stock	13,000	$ 3.28	D	Â
Employee Stock Option	Â (1)	12/16/2020	Common Stock	25,000	$ 3.1	D	Â
Employee Stock Option	Â (1)	12/12/2021	Common Stock	9,500	$ 7.59	D	Â
Employee Stock Option	Â (1)	12/18/2022	Common Stock	12,900	$ 8.64	D	Â
Employee Stock Option	Â (1)	12/17/2023	Common Stock	20,000	$ 3.02	D	Â
Employee Stock Option	Â (1)	12/04/2024	Common Stock	14,100	$ 13.8	D	Â
Employee Stock Option	Â (2)	01/25/2026	Common Stock	18,000	$ 7.54	D	Â
Employee Stock Option	Â (3)	07/25/2026	Common Stock	6,000	$ 8.42	D	Â
Employee Stock Option	Â (4)	01/25/2027	Common Stock	30,000	$ 4.17	D	Â
Employee Stock Option	Â (5)	02/16/2028	Common Stock	75,000	$ 3.2	D	Â
Employee Stock Option	Â (6)	08/06/2028	Common Stock	10,000	$ 2.52	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lantz Keri C/O ACHILLION PHARMACEUTICALS, INC. 300 GEORGE STREET NEW HAVEN,Â CTÂ 06511	Â	Â	Â See Remarks	Â

Signatures

/s/ Keri Lantz	01/07/2019
**Signature of Reporting Person	Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option is fully vested and exercisable.
(2)	This option was granted on January 25, 2016 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
(3)	This option was granted on July 25, 2016 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
(4)	This option was granted on January 25, 2017 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
(5)	This option was granted on February 16, 2018 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.
(6)	This option was granted on August 6, 2018 and vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter.

Â

Remarks:

ViceÂ PresidentÂ ofÂ Finance,Â CorporateÂ Controller,Â InterimÂ PrincipalÂ FinancialÂ OfficerÂ andÂ InterimÂ Principa

SeeÂ ExhibitÂ 24.1,Â PowerÂ ofÂ Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.